TG Therapeutics, Inc. (TGTX) News

TG Therapeutics, Inc. (TGTX): $4.57

0.32 (+7.53%)

POWR Rating

Component Grades













Add TGTX to Watchlist
Sign Up

Industry: Biotech


of 398

in industry

Filter TGTX News Items

TGTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

TGTX News Highlights

  • For TGTX, its 30 day story count is now at 20.
  • Over the past 28 days, the trend for TGTX's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
  • TG, AHI and CYN are the most mentioned tickers in articles about TGTX.

Latest TGTX News From Around the Web

Below are the latest news stories about Tg Therapeutics Inc that investors may wish to consider to help them evaluate TGTX as an investment opportunity.

AdaptHealth Corp. (AHCO) Q4 Earnings Miss Estimates

AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -62.50% and 1.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update

Conference call to be held Tuesday, March 1, 2022 at 8:30 AM ETNEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, March 1, 2022 at 8:30 AM ET to discuss results for the fourth quarter and year-end 2021 and provide a business outlook for 2022. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-2

Yahoo | February 24, 2022

2 Wildly Oversold Stocks That Could Explode Higher

The stock market is often an exercise in reverse psychology. When a stock goes up, investors instinctively want to get a piece of the action. Likewise, when a stock drifts to the bottom, the natural inclination is to run away. But any investor worth their salt knows they need to battle against those natural impulses as the bottom is often the most appealing starting point; because it is from there that the real gains are made.

Marty Shtrubel on TipRanks | February 15, 2022

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 24 – 26, 2022, in West Palm Beach, Florida. Abstracts are now available online and can be access

Yahoo | February 15, 2022

Ublituximab In MS Is The Heart Of TG Therapeutics, And The Heart Is Safe

TG Therapeutics (TGTX) is giving the biopharma market the scare of its life, with the FDA looking more and more likely to come up with a negative opinion on the approval of Ublituximab+Umbralisib (Ukoniq), also known as U2, in Chronic Lymphocytic Lymphoma or CLL. The FDA’s beef is directed against...

Avisol Capital Partners on Seeking Alpha | February 8, 2022

TG Therapeutics slips on concerns over FDA probe on cancer medicine

TG Therapeutics <> is trading lower after the FDA announced an ongoing investigation over the increased risk of death related to the companys cancer medicine

Seeking Alpha | February 3, 2022

TG Therapeutics (TGTX) Moves 17.7% Higher: Will This Strength Last?

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Yahoo | January 31, 2022

Jefferies Thinks TG Therapeutics’ Stock is Going to Recover

Jefferies analyst Chris Howerton maintained a Buy rating on TG Therapeutics (TGTX – Research Report) yesterday and set a price target of $56.00. The company's shares closed last Thursday at $8.27, close to its 52-week low of $8.05. According to, Howerton is ranked 0 out of 5 stars with an average return of -19.2% and a 25.0% success rate. Howerton covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Liquidia Technologies, and Alaunos Therapeutics. TG Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $44.40, representing a 436.9% upside. In a report issued on January 21, H.C.

Catie Powers on TipRanks | January 28, 2022

Analysts’ Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (TGTX) and Sanofi (OtherSNYNF)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on TG Therapeutics (TGTX – Research Report) and Sanofi (SNYNF – Research Report). TG Therapeutics (TGTX) In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on TG Therapeutics, with a price target of $68.00. The company's shares closed last Thursday at $8.27, close to its 52-week low of $8.05. According to TipRanks.

Christine Brown on TipRanks | January 28, 2022

64 Biggest Movers From Yesterday

Check out these penny stocks insiders are buying Losers ION Geophysical Corporation (NYSE: IO ) shares fell 53.6% to settle at $0.51 on Thursday. Epizyme, Inc. (NASDAQ: EPZM ) shares dipped 44.2% to close at $1.06 on Thursday after the company priced an underwritten public offering of 56,666,667 shares at $1.50 per share, before underwriting discounts. TG Therapeutics, Inc. (NASDAQ: TGTX ) dropped 40.5% to settle at $8.27 on Thursday. TG Therapeutics said the FDA imposed partial clinical hold on select studies of U2 and its components for CLL and NHL. Cyngn Inc. (NASDAQ: CYN ) tumbled 35.7% to close at $1.62. PetVivo Holdings, Inc. (NASDAQ: PETV ) fell 35% to close at $1.30. PetVivo recently announced distribution of its veterinary medical device, SPRYNG, by Vetcove, Inc. Advanced Human...

Benzinga | January 28, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6203 seconds.